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CONNECTIVE TISSUE ACTIVATION 
XIV. Composition and Actions of a Human Platelet Autacoid Mediator 
C. WILLIAM CASTOR, JAMES C. RITCHIE, CHARLES H. WILLIAMS, JR., MARY E. SCOTT, 
SHERRY L. WHITNEY, STEPHEN L. MYERS, TOD B. SLOAN, and BYRON E. ANDERSON 
Connective tissue activating peptide-I11 (CTAP- 
111) isolated from human platelets is a potent mitogen 
for human connective tissue cells in culture in addition 
to stimulating glycosaminoglycan synthesis, glucose 
consumption, and lactate formation. The amino acid 
composition of apparently homogeneous CTAP-111 was 
determined, confirming the presence of two disulfide 
links and providing a calculated molecular weight of 
11,633 daltons. Comparison of the mitogenic activity of 
serum and plasma-serum suggests that CTAP-I11 is a 
major mitogenic component of human serum. Seventeen 
strains of human connective tissue cells (synovial, carti- 
lage, dermal and thyroid) incorporated 13H]-thymidine 
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a t  up to 30 times control a t  levels under the influence of 
microgram quantities of CTAP-I11 and caused detect- 
able increases in thymidine incorporation a t  levels as 
low as  10-29 ng/ml. Prostaglandin E, (0.01 pg/ml) and 
dibutyryl cyclic AMP (25 pg/ml) potentiated the glyco- 
saminoglycan stimulating effect of CTAP-111, but not its 
mitogenic effect. Cycloheximide and actinomycin D 
blocked the biologic actions of CTAP-111. Cortisol and 
penicillamine had little effect on the mitogenic activity 
of CTAP-111, whereas antirheumatic agents such as ace- 
tylsalicylic acid and phenylbutazone opposed the mito- 
genic activity when added to cultures at  clinically rele- 
vant concentrations. A weak antiheparin factor secreted 
by platelets, low affinity platelet factor 4 (LA-PF,), was 
shown to be similar to CTAP-I11 in biologic actions, 
electrophoretic mobility, amino acid composition, and 
antigenic determinants. 
Human synovial cells have been “activated” in 
vitro both by incubation with living lymphocytes, 
thrombocytes, and polymorphonuclear leukocytes and 
by incubation with extracts of these blood cells (1-3). 
Connective tissue activation was defined as a con- 
stellation of metabolic events occurring during the re- 
parative phase of inflammation, including stimulation 
of cellular energy metabolism, glycosaminoglycan 
(GAG) synthesis, proliferation, and collagen synthesis 
(4). Protein moieties extractable from leukocytes and 
platelets that stimulate such “activation” were termed 
connective tissue activating peptide@) ICTAP (s)]. The 
Arthritis and Rheumatism, Vol. 22, No. 3 (March 1979) 
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Figure 1. Isolation of CTAP-I11 from human platelets. Stages 111 and 
1V may have to be executed twice in order to obtain CTAP-111, which 
is approximately 95% homogeneous as judged by disc gel elec- 
trophoresis. 
isolation, composition, and biologic actions of CTAP-I 
(from lymphoid tissue) and CTAP-I1 (from the human 
HEp-2 tumor cell line) have been reported in detail (5- 
14). 
Isolation of CTAP-111 from human platelets was 
originally accomplished by assaying for the GAG stim- 
ulating activity of fractions generated during the prepa- 
rative process (4,14). CTAP-I11 clearly stimulated GAG 
synthesis in human dermal fibroblast cultures as well as 
synovial cultures, and the biologic activity was de- 
stroyed by thiols, unlike the situation with CTAP’I and 
-11 which were protected by thiols. CTAP-111, isolated 
on the basis of its GAG stimulating property, was then 
found to stimulate DNA synthesis in human synovial, 
cartilage, dermal, and thyroid fibroblasts (1 5) .  Platelets 
aggregated by bovine thrombin were shown to extrude a 
CTAP-111-like activity into the aqueous suspending me- 
dium (4,16), suggesting that this mediator might be re- 
leased in a physiologic setting like the clotting process. 
More recent studies show that CTAP-I11 stimulates for- 
mation of chondroitin-4/-6 sulfate, promoting synthesis 
of the carbon chain as well as incorporation of ”SO,’ 
(17). Of interest is the observation that platelets from 
patients with rheumatoid arthritis have a quantitative 
deficit in CTAP-I11 activity (1 8). 
Others have characterized thrombin releasable 
platelet proteins utilizing antiheparin activity as an as- 
say method (19). Fractions eluted from a heparin-aga- 
rose column were called low affinity platelet factor 4 
(LA-PF,) and high affinity platelet factor 4 (HA-PF,) on 
the basis of the sodium chloride concentrations required 
to effect elution from the column. These proteins dif- 
fered in their antigenic make-up and antiheparin activ- 
ity and had apparent molecular weights similar to that 
(1 1,633 daltons) reported for CTAP-111. 
This report provides information concerning the 
amino acid composition of CTAP-I11 and the cell spec- 
trum sensitive to the mitogenic action of this mediator. 
Data concerning the mechanism of action and the effect 
of selected drugs on the biologic activity of CTAP-111 
are presented. In addition, data are reported which in- 
dicate that CTAP-I11 is probably identical to low affin- 
ity platelet factor 4 (LA-PF,), an “antiheparin” factor 
extruded by platelets in the course of platelet release re- 
actions. Further, CTAP-I11 is similar in some respects to 
P-thromboglobulin (P-TG), also known to be released 
from platelets during aggregation. 
MATERIALS AND METHODS 
Culture methods 
Human synovial membrane specimens were obtained 
at arthrotomy or amputation, a portion was fixed for histol- 
ogy, and the remainder divided into 1 mm3 fragments and ex- 
planted to develop monolayer cultures as reported previously 
(20). Human dermal and thyroid fibroblast monolayer cul- 
tures were generated in a similar manner, while chondrocytes 
were grown from enzymatically disaggregated cartilage from 
osteoarthritic human femoral heads removed during total hip 
arthroplasty (2 1). Human and mammalian cell lines were also 
recovered from frozen storage for use in these studies as 
needed. Routine culture medium for connective tissue cells 
consisted of 80% synthetic medium 1066, 10% fetal calf serum, 
and 1Wo heat inactivated human serum supplemented with L- 
glutamine, penicillin, streptomycin, and 0.02 M Hepes buffer. 
Human serum was inactivated by incubation at 56°C for 1 
hour. Cells were counted with a Coulter Model B cell counter 
(Coulter Electronics, Hialeah, Florida). 
Isolation of connective tissue activating peptide-I11 
(CTAP-111) from human platelets. The active platelet prin- 
ciple was extracted into an acid-ethanol medium and sub- 
sequently precipitated by acetone as described earlier (4), with 
several modifications (see Figure 1). Currently, outdated 
platelets are extracted with stirring in 10 volumes of acid-eth- 
anol (5% 1.25 N HCl: 95% ethanol) for 1 hour at room tem- 
perature followed by centrifugation at 17,300 g (10 minutes, 
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21 “C). Precipitation of active material from the supernatant 
of the acid-ethanol extract was accomplished by adding 3 vol- 
umes of acetone at room temperature and allowing the mix- 
ture to stand for 1 hour. The precipitate was collected in 1.0 M 
acetic acid and dialyzed at 6°C against 30 volumes of 1.0 M 
acetic acid containing 3.6% NaCl. After 16 hours of dialysis, 
the precipitate that had formed was removed by centrifuga- 
tion at 5OC for 10 minutes at 17,300 g. This supernatant solu- 
tion was further dialyzed against 0.05 M phosphate buffer, pH 
7.0, containing 0.15 M NaCl and any precipitate resulting 
from this step was removed by centrifugation. 
The crude extract was then chromatographed on 
Sephacryl S-200 (5 X 55 cm) equilibrated with phosphate buf- 
fered saline. Material emerging from the column in the elu- 
tion position of cytochrome C was subsequently further puri- 
fied by ion exchange chromatography on CM-Sephadex C-50 
(2 x 6 cm). This column was equilibrated with 0.1 M phos- 
phate buffer, pH 6.0, and the major portion of the CTAP-111 
was eluted with 0.1 M phosphate, pH 6.0, containing 0.25 M 
sodium chloride. It was frequently necessary to repeat the gel 
permeation chromatography and ion exchange chromatogra- 
phy, sometimes including elution from a cation exchanger 
with a linear salt gradient (4), to achieve preparations homog- 
eneous by SDS disc gel electrophoresis (22) and disc gel elec- 
trophoresis in an acid-urea buffer system, (23).The platelet 
materials may be lyophilized without loss of activity after ace- 
tone precipitation and acid-salt precipitation. 
Amino acid analysis. A Beckman 120B amino acid an- 
alyzer equipped with long path length cells was used and sam- 
ples were injected from precalibrated loops. Resin (type DC- 
I A) and buffer concentrates (Pico-11) for the single column 
systems were obtained from Durrum and Pierce respectively. 
Samples were hydrolyzed, after thorough degassing to 60 p, in 
1 ml HCl with or without 20 pl of dimethylsulfoxide for the 
conversion of half-cystine to cysteic acid (24). Samples were 
analyzed in duplicate. The data were normalized to give near 
integral values (residues/mole) for the six most reliable amino 
acids: aspartic acid, 10.14 and 11.82; glutamic acid, 13.97 and 
12.19; glycine, 10.77 and 8.37; alanine, 8.10 and 7.85; leucine, 
7.16 and 10.73; and lysine, 9.72 and 10.97; the first figure re- 
fers to CTAP-I and the second to CTAP-111. The data for 
CTAP-I1 were normalized taking methionine equal to 1 .O. 
Free thiol determination. No free thiol could be de- 
tected in the absence of guanidinium chloride. Thiol was de- 
termined in 0.3 M phosphate buffer, pH 7.0, containing 3.3 M 
guanidinium chloride and 0.32 mM 5,5’-dithiobis (2-nitro- 
benzoic acid). 
Preparation of antibodies to CTAP-111. Five 18-week- 
old AJ mice (Jackson Laboratories) were immunized accord- 
ing to the method of Tung et a1 (25) utilizing 0.2 ml in- 
traperitoneal injections of a 1:9 emulsion of 0.05 M sodium 
acetate, plus 0.3 M NaCl, pH 6.8, and complete Freunds adju- 
vant (Miles Laboratories). Three mice were each injected with 
approximately 100 pg CTAP-111 in the emulsion on days 0, 15, 
22, and 28. Ascites fluid was collected twice weekly from day 
54 through 83. Antibody to CTAP-I11 was also raised in rab- 
bits using multiple injection sites, and a specific immuno- 
absorbent prepared by a glutaralydehyde crosslinking method 
(26). The presence of antibodies to CTAP-111 in ascitic fluid 
or serum was determined by the double immunodiffusion 
method of Ouchterlony (27). 
Preparations of low affinity platelet factor 4 (LA-PF,), 
platelet factor 4 (PF,), and p-thromboglobulin (P-TG). Dr. 
Stefan Niewiarowski (Thrombosis Research Center, Temple 
University, Philadelphia) kindly made available purified 
preparations of LA-PF, (also called low affinity antiheparin 
factor), high affinity platelet factor 4 (HA-PF,, also called 
PF,), and rabbit antisera raised against these proteins. Both 
LA-PF, and PF, were isolated from the supernatant fluid after 
thrombin aggregation of fresh washed human platelets (28). 
The authors are grateful to Dr. Duncan S. Pepper (Edinburgh 
and Southeast Scotland Regional Blood Transfusion Service) 
for his gifts of p-thromboglobulin @-TG)(29) and PF,. Ra- 
dioimmunoassay of p-TG and related proteins was performed 
with commercial reagents (Amersham Corporation). 
Preparation of “plasma-serum.” Preparation of 
“plasma-serum’’ was carried out in a manner similar to that 
described by Ross (30). This preparation has the protein com- 
postion of serum except that it lacks substances usually con- 
tributed by the platelet component of the clotting process. Cit- 
rate anticoagulated blood was centrifuged at  room 
temperature for 15 minutes at 1,000 g and the resulting 
plasma freed of residual particulate material by centrifugation 
at 22,000 g for 30 minutes. Calcium chloride (1 .O M) was then 
added to a concentration of 20 mM, and the plasma prepara- 
tion incubated for 2 hours at 37°C. After centrifugation at 
22,000 g for 30 minutes, the fibrin mass was discarded and the 
supernatant “plasma-serum” was dialyzed against 40 volumes 
of Ringer’s solution at 4°C for 24 hours. 
Measurement of tritiated thymidine incorporation into 
fibroblast DNA. To measure mitogenic activity of test sub- 
stances, tritiated thymidine (specific activity 5 1.7 Ci/mM) was 
added to cultures and the radioactivity in cell lysates deter- 
mined. Cells were plated, lo4 cells/microtiter well (Falcon, 
Linbro, or Costar) in a serum-poor medium (Eagle’s synthetic 
medium 97%, fetal calf serum 3%, with penicillin, streptomy- 
cin, L-glutamine, and 0.02 M Hepes buffer) and incubated in 
a humidified chamber at 35-37°C. Test cells were incubated 
for at least 20 hours with 100 p1 of medium. Test fractions and 
vehicles were then added (5-15 pl/well) and incubation was 
continued for 24 hours when tritiated thymidine (1.5 @/I5 
pl Eagle’s synthetic medium/well) was added and incubation 
resumed for an additional 24 hours. The supernatant medium 
was aspirated, discarded, and the cell sheets were washed 
twice, each separately, with phosphate-buffered saline (pH 
7.0), 5% trichloroacetic acid and absolute methanol. After air 
drying (at 35”C), the cell sheets were lysed for 1 hour at 37°C 
with 50 pl of 0.3 N sodium hydroxide. Forty microliters of cell 
lysate were spotted on glass paper (glass fiber filter paper, 
Whatman grade 934 AH, H. Reeve Angel, Inc., Clifton, New 
Jersey), dried, and the tritium content quantitated in a Tricarb 
liquid scintillation spectrometer. 
Chemical assay procedure for mediators of connective 
tissue activation. In typical experiments, 1 x lo6 normal syno- 
vial cells were plated in T-15 flasks containing 2 ml of stan- 
dard serum-containing medium. After 4 to 6 hours of in- 
cubation at 37”C, the medium was replaced with 2 ml of 
Eagle’s synthetic medium buffered to pH 7.4 with 0.02 M 
Hepes buffer and supplemented with penicillin, streptomycin, 
and L-glutamine. Experimental flasks received 0.1 to 0.3 ml of 
test materials and control flasks received equivalent volumes 
of an appropriate vehicle. Flasks were incubated at 35 to 37°C 
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Table 1. Purification of CTAP-I11 biologic activities 
Specific activity; Relative specific activity 
Total GAG DNA GAG DNA 
protein (gm) stimulation stimulation stimulation stimulation 
- - Platelets, 25 ml 7.960 - - 




CTAP-I11 from 0.0 12 6.70 2.618 3.12 3.20 
Specific activity for GAG stimulation was calculated in terms of “CTAP units”/mg of CTAP pro- 
tein. (See Methods.) DNA stimulating activity was defined in terms of the incremental incorporation of 
’H-thymidine caused by addition of 1% human serum to resting cells. This difference was arbitrarily 
called 100 “DNA stimulating units.” Thus, if buffer and 1% serum treated cultures showed 1,000 CPM 
and 6,000 CPM, respectively, then 5,000 CPM over buffer control levels would represent 100 “DNA 
stimulating units.” A CTAP-I11 treated culture with I 1 , 0 0 0  CPM would be judged to have 200 units of 
DNA stimulating activity. These arbitrary units were divided by the CTAP-I11 protein concentration 
(mg/ml) to provide a specific activity value. 
for 40 hours after which total cell protein and total medium 
hyaluronic acid were determined. Protein was measured by 
the method of Oyama and Eagle (31). Hyaluronic acid or sul- 
fated glycosaminoglycans were isolated from nonserum-con- 
taining medium by using cetylpyridinium chloride without 
prior proteolysis (3), and uronic acid was determined by a 
modified carbazole method (32). 
The hyaluronic acid formation rate was expressed as 
pg hyaluronic acid/mg cell protein/24 hours. Experimental 
and control groups consisted of 2 to 4 flasks and data from 
each were expressed as mean -+ one standard deviation. Be- 
cause incremental glycosaminoglycan synthesis by synovial 
cultures is essentially linear with respect to incubation time 
and the quantity of CTAP-I11 added to the cultures, the quan- 
tity of CTAP-I11 “biologic activity” in a sample may be esti- 
mated by using the following relation (4): 
(units/ml) Ai - Ao 
10 v CTAP = 
where A, represents the rate of hyaluronic acid synthesis, pg 
of hyaluronate/mg cell protein per 24 hours in stimulated cul- 
tures, and A. is the same measurement in control cultures. V 
is the volume of test sample added to the standard assay cul- 
tures. A unit .of CTAP-I11 biologic activity is thus defined as 
that amount which stimulates a standard synovial culture to 
augment its hyaluronic acid synthesis rate by 10 pg hyaluronic 
acid/mg of cell protein/24 hours. 
Miscellaneous methods. Highly purified CTAP-I11 
was radiolabeled with 1251 by a method utilizing chloramine-T 
(33). Isoelectric focusing was performed in 7.5% poly- 
acrylamide gels containing 2% ampholytes (pH 3-10) and 5% 
glycerol, and gels were stained with Coomassie Brilliant Blue 
R. 
RESULTS 
Properties of CTAP-111. Previous studies using 
gel permeation chromatography and SDS gel elec- 
trophoresis indicated that the molecular weight of 
highly purified CTAP-I11 was approximately 9,300 dal- 
tons (4). The molecule was believed to be a cationic pro- 
tein on the basis of its binding to ion exchange materials 
and migration characteristics in disc gel electrophoresis. 
Since 2-mercaptoethanol treatment destroyed both the 
mitogenic and GAG stimulating activity of the peptide, 
it was thought that one or more disulfide groups were 
essential for these biologic activities. Because this treat- 
ment did not generate additional protein fragments de- 
tectable by disc gel electrophoresis, it was believed that 
CTAP-I11 exists as a single polypeptide chain whose 
conformation was influenced in a critical fashion by in- 
trachain disulfide linkage (4). 
Current data confirm the cationic nature of 
CTAP-111, since in isoelectric focusing studies it appears 
as a single band with a pH, of 8.5 k 0.4 (six determina- 
tions). CTAP-I11 also appears to be relatively heat 
stable, since purified samples dissolved in neutral phos- 
phate buffered saline could be placed in a boiling water 
bath for 5 minutes with loss of GAG or DNA stimulat- 
ing properties. 
Isolation, chemical characteristics and actions of 
CTAP-111. The isolation procedures for CTAP-I11 lead 
to an increase in specific activity with respect to both 
the GAG and DNA stimulating actions. As shown in 
Table 1, extraction of the active principle(s) into an 
acid-ethanol vehicle results in an initial 16-fold purifi- 
cation, since all of the extractable biologic activity is re- 
covered in 6% of the original platelet protein. Figure 2 
demonstrates that the molecular weight fraction corre- 
sponding to cytochrome C is a major constituent of this 
initial crude extract. The major active fraction after gel 
permeation chromatography is primarily in the molecu- 
lar weight range of cytochrome C (Figure 2). Ion ex- 
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Figure 2. Polyacrylamide gel electrophoresis. The SDS gels indicate 
that the initial extraction of platelets with acid-ethanol selects heavily 
in favor of low molecular weight components, and that gel per- 
meation chromatography further simplifies the mixture. The prepara- 
tion electrophoresed on the acid-urea gel was a 0.25 M NaCl fraction 
from a CM-Sephadex column which was then refractionated on a 
Sephacryl S-200 column. At least 95% of the protein resides in a single 
band. Similar purification may be achieved by eluting from CM- 
Sephadex with a linear salt gradient as reported earlier (4). 
change chromatography results in an essentially homog- 
eneous preparation as determined by disc gel 
electrophoresis in an acid-urea system (Figure 2). Fur- 
ther evidence suggesting that the final CTAP-111 prepa- 
ration was homogeneous was obtained by radiolabeling 
the protein (33) with I2’I and subjecting this product to 
electrophoresis in both acid-urea (23) and SDS poly- 
acrylamide gel systems (22). The gels were sliced into 
consecutive 1.2 mm segments and their radioactivity 
was measured with a gamma counter (Automatic 
Gamma System, Model 1185, Searle Analytic, Inc.). 
Each gel system showed only one radioactive peak, and 
in each case it corresponded closely with the position of 
unlabeled CTAP-111 run in parallel gels. The final in- 
creases in relative specific activity for the GAG and 
DNA synthesis stimulating activities are similar (Table 
The amino acid composition of two preparations 
of apparently homogeneous CTAP-111 was determined 
and the data are presented in Table 2. It is clear that 
CTAP-111 resembles CTAP-I and -11 with respect to the 
striking deficiency of aromatic amino acid residues, but 
1). 
differs in that it contained 5 half-cystine residues which 
are derived from 2 disulfide bonds and a single masked 
sulfhydryl group. In the presence of a moderate concen- 
tration of guanidinium chloride, 0.8 M of thiol was de- 
tected per mole of protein. The best fit molecular weight 
derived from amino acid analysis is 11,633 daltons for 
CTAP-111 and 11,233 for CTAP-I. It should be noted 
that the molecular weight estimate for CTAP-I has been 
revised downward from previously published values by 
utilizing the normalization procedure noted in the 
Methods section. 
Data in Figure 3 show that concentrations of 
CTAP-I11 in the range of 29-200 ng/ml produce easily 
detectable increments in DNA synthesis in human sy- 
novial cell cultures. A half-maximal response was elic- 
ited by CTAP-111 at 1 X 10 -’ M concentrations. Similar 
concentrations appear to be required for the stimulation 
of increased hyaluronic acid synthesis (measured in 
terms of uronic acid) and for stimulation of 35S0,’ in- 
corporation into sulfated glycosaminoglycans. 
Efforts to increase the apparent sensitivity of 
adult human connective tissue cells to the mitogenic ac- 
tion of CTAP-I11 by prolonging the period of serum 
deprivation did not materially affect results. Further, 
the murine 3T3 cell line gave essentially the same data 
as human cells with respect to its sensitivity to the mito- 
genic effect of CTAP-111. The enrichment of the final 
preparation with respect to a specific protein (CTAP- 
111) is clearly greater than the enhanced (apparent) spe- 
Table 2. Amino acid composition of CTAP-I, 11, and 111 
Residues/mole 
~~ ~ 
CTAP-I CTAP-I1 CTAP-Ill 
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cific activities with respect to stimulation of DNA and 
GAG synthesis. Although this apparent dichotomy may 
be explained by damage to the protein (and consequent 
loss of specific biologic activity) during the late stages of 
purification, it should also be pointed out that other 
(non-CTAP-111) proteins are present in platelets which 
stimulate GAG and DNA synthesis. There is a higher 
molecular weight anionic protein, antigenically unlike 
CTAP-111 (to be reported in detail elsewhere), which is 
systematically removed during the purification of 
CTAP-111, hence reducing the final specific activity of 
CTAP-111 below what would have been anticipated if 
all of the GAG and DNA stimulating activities had re- 
sided in a single platelet protein species. Further com- 
plicating the estimate of “specific activity” of purified 
CTAP-111, and suggesting that the reported values may 
well be minimum values, is the fact that the purified 
protein adsorbs rapidly to glass and other materials. It 
seems likely that the measured protein concentrations 
are overestimates of the amount that actually gets into a 
bioassay after Millipore filter sterilization, storage in 
glass vials, and pipetting into test culture flasks. 
It is pertinent that when platelet preparations are 
adsorbed on an immunoadsorbent preparcd from gluta- 
raldehyde crosslinked rabbit globulins containing anti- 
bodies against CTAP-111, the CTAP antigen is removed. 
Elution of the immunoadsorbent with acid glycine buf- 
fer releases antigen (CTAP-111) which has characteristic 
electrophoretic mobility and GAG and DNA stimulat- 
ing properties. 
CTAP-111 as a major serum mitogen for human 
connective tissue cells. “Plasma-serum” prepared in the 
absence of platelet aggregation has less than half the ca- 
pacity of conventional serum to stimulate DNA syn- 
thesis in human connective tissue cells. Data in Table 3 
demonstrate the reduced mitogenic properties of two 
separate “plasma-serum’’ preparations tested on a single 
connective tissue cell strain, and secondly, show that a 
second cell strain exhibited the same defective response. 
The platelet factor could be added back in purified form 
to the “plasma-serum” or conventional serum with en- 
hancement of DNA-stimulating properties of these sera. 
The individual plasma proteins tested caused no stimu- 
lation of DNA synthesis and, in fact, in some cases ap- 
peared to be inhibitory. 
Responsive cell spectrum. CTAP-111 stimulated 
DNA synthesis in all of the human connective tissue 
cell strains that were tested (Table 4). A single adult hu- 
man arterial endothelial cell strain was also responsive 
to CTAP-111. On the other hand, DNA synthesis in es- 
tablished human cell lines and in normal human pe- 
ripheral blood lymphocytes was not stimulated by 
CTAP-111. While most nonhuman mammalian cell 
strains and lines usually did not respond to CTAP-111, 
canine synovial cells and normal rat kidney fibroblasts 
were exceptions and showed a clear mitogenic response. 
It was of interest that although both guinea pig and ca- 
nine lung fibroblasts failed to respond to CTAP-I11 with 
increased DNA synthesis, both showed appreciable in- 
creases in glycosaminoglycan formation. 
Factors related to the mechanism of action of 
CTAP-111. CTAP-111 appears to be very rapidly bound 
to human connective tissue cells in culture, because cul- 
tures exposed for less than 2 minutes to the stimulatory 
peptide in effective concentrations were clearly com- 
mitted to accelerated metabolic effort. As shown in 
Table 5, both PGE, and cyclic AMP, in concentrations 
too small to cause direct stimulation of GAG synthesis, 
nevertheless substantially potentiate the action of 
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Table 3. Effect of serum proteins on connective tissue cell DNA synthesis 
Experiment no. [’HI Thymidine 
cell strain Additives* (CPM/8000 cells) Exper/Control 
I 
Synovium (EW) Buffer 1,485 f 167 - 
CTAP-III(14.6 pg/ml) 18,118 f 1,826 12.2 
Plasma-serum (A) 8,363 k 646 5.6t 
Serum (A) 18,493 f 2,602 12.5 
Plasma-serum + CTAP-I11 24,939 f 2,157 16.8 
Serum + CTAP-111 24,096 f 3,5 15 16.2 
2 
Synovium (EW) Buffer 1,617f 272 - 
CTAP-III(14.6 pg/ml) 19,123 f 2,522 11.8 
Plasma-serum (B) 7,064 rt_ 1,635 4.4t 
Serum (B) 24,8 19 f 2,762 15.3 
3 
Synovium (ORS) Buffer 6 1 5 f  I50 - 
CTAP-III(14.6 pg/ml) 18,223 f 4,559 29.6 
Serum (B) 20,135 f 2,720 32.7 
Plasma-serum (B) 6,178 f 1,274 10.0 t 
4 
Synovium (PR) Buffer 1,179f 145 - 
CTAP-III(14.6 pg/ml) 12,834 f 1,031 10.9 
Albumin (108 pg/ml) 5 1 2 f  136 0.4 
crglobulins (80.7 pg/ml) 1,0302 203 0.9 
Pglobulins (33.5 pg/ml) 9 5 5 f  136 0.8 
Hemoglobin (127.8 pg/ml) 6 5 6 2  58 0.6 
* Serum and “plasma-serum” prepared from donors “A” and “B” were added, 5 pl per well containing 
100 pl of standard assay medium. Serum protein fractions were purchased from Calbiochem, La Jolla, 
California. 
t “Plasma serum” had substantially less capacity to stimulate DNA synthesis than serum prepared 
from clotted blood in the conventional way. 
CTAP-111 in causing accelerated GAG formation. In- 
terestingly, both cyclic nucleotides and prostaglandins 
tended to inhibit rather than potentiate the mitogenic 
action of CTAP-111. It is noteworthy that much higher 
Table 4. Mitogenic effect of CTAP-111 on cultured cells 
Cells Exper/Control’ 




Thyroid ( I )  




HEp2 (Ca larynx) 
Mammalian cell strains 





Human continuous lines 
Mammalian continuous lines 
~ 
9.5 2 5.5 
6.0 * 1.7 












* Mean f 1 standard deviation. 
concentrations of dibutyryl cyclic AMP and PGE,, 
which are known to directly stimulate GAG synthesis 
(8,9), are also ineffective in stimulating DNA synthesis 
in these human connective tissue cells. Dibutyryl cyclic 
Table 5. Factors modifying CTAP-111 regulation of human connective 
tissue cells 
Synthesis of:t 
Agents GAG DNA 
_______ ~ 
Potentiators 
0.01 jig PGEI + CTAP-III/CTAP-111 
0.10pg PGEI + CTAP-III/CTAP-I11 
25 p g  Db cAMP + 




Cyclohex + CTAP-III/CTAP-I11 
Ara-C + CTAP-III/CTAP-I11 
ACT-D + CTAP-III/CTAP-111 
2.9 0.73 
3.7 0.77 





* Cycloheximide was used in a concentration of 10 pg/ml, acti- 
nomycin D in a concentration of 0. I pg/ml, and cytosine arabinoside 
in a concentration of 10 pg/ml. 
t Data are recorded as the ratio: experimental/control. 
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Table 6. Comparison of autacoid and hormone effects on DNA synthesis in human connective tissue cell 
cultures* 
'H incorporation, 
Hormone CPM/8000 cells Experimental 































13. I pg/ml 
16.4 pg/ml 











10 m units/ml 
100 m units/ml 
47.6 pg/ml 





I .O pg/ml 
3.0 pg/ml 
1 .O pg/ml 
1,621 f 227 
2,939 f 237 
5 , 2 3 9 f  901 
18,792 f 2,879 
2,045 f 342 
2,858 f 551 
2,682 f 198 
12,009 f 2,834 
1 ,709f  476 
6 , 0 8 4 f  649 
30,624 f 3,687 
8,212 & 1,572 
1,645 f 220 
1 ,176f  516 
3,017 f 225 
7,378 f 1,773 
12,067 f 772 
33,949 f 5,258 
40,843 f 1,679 
7,306 f 416 
33,514k 584 













































* Experiments I and 3 were carried out with normal synovial cell strains from the right and left knees, 
respectively, and each cell strain was used at the sixth subculture. Experiment 2 utilized cells from an- 
other normal human synovial membrane in the fifth trypsin passage; experiment 4 used seventh passage 
synovial cells. 
t Experimental values were compared to the appropriate vehicle values, except for the last three lines 
of experiment 4, where agonist + cortisol values were compared to the appropriate agonists alone. 
$ Fibroblast growth factor, FGF, was purchased from Collaborative Research, Inc., Waltham, Massa- 
chusetts. 
8 TSH is thyrotropin, NIH - TSH - B6, bovine. LH is luteinizing hormone, NIE - LH - B8, bovine. 
GMP was also ineffective in modifying tritiated thymi- 
dine incorporation into DNA in human synovial cul- 
tures. 
Comparison of mitogenic effects of autacoid and 
hormones. The marked potency of CTAP-111 as a mito- 
gen for human synovial connective tissue cells is re- 
corded in Table 6. CTAP-111 (5.1 pg/ml) increased tri- 
tiated thymidine incorporation 4 to 6 times more than 
did CTAP-I and -11, even though the latter were used at 
higher protein concentrations. Commonly, human 
CTAP-I and -11 exhibit no mitogenic capability against 
human connective tissue cells. Fibroblast growth factor 
(FGF) clearly caused a minor increase in adult human 
synovial cell DNA synthesis at 250 ng/ml, an effect in- 
distinguishable from that of CTAP-111 at the same con- 
centration. This contrasts with the reported stimulation 
of neonatal human skin fibroblasts by 25 ng FGF/ml 
(34). Both thyrotropin and luteinizing hormone prepa- 
rations stimulated synovial cell DNA synthesis. In the 
case of the TSH preparation, the stimulatory action was 
opposed by the concurrent addition of cortisol to the 
culture. Cortisol alone did not modify [3H]-thymidine 
incorporation, and it did not depress or potentiate the 
action of CTAP-I11 at the two concentrations tested. In- 







CTAP- ICC t DRUGS 
Figure 4. The bars represent the mean [3H]-thymidine incorporation f 1 .O standard deviation. Aspirin, hydroxy- 
chloroquine, phenylbutazone, and indomethasone were included in concentrations encountered in clinical practice. 
sulin in supraphysiologic concentrations modestly stim- 
ulated DNA synthesis. 
Drug regulation of CTAP-111 enhanced DNA 
synthesis. The possibility that drugs might modify the 
capability of CTAP-I11 to stimulate DNA synthesis in 
connective tissue cells was explored by using microtiter 
well cultures. Concentrations of cortisol as high as those 
Figure 5. Anti-CTAP-111 (prepared in mice) reacts with both CTAP- 
I11 and LA-PF, in lines of identity, as does anti-LA-PF, (prepared in 
rabbits). 
found in Cushing’s disease had neither suppressive nor 
stimulatory effects on CTAP-induced enhancement of 
DNA synthesis (Figure 4). Cortisol in concentrations 
ranging from 0.01 pg/ml to 2.0 pg/ml (data not shown) 
also did not modify CTAP-111-enhanced DNA syn- 
thesis. High concentrations of penicillamine caused mi- 
nor reduction in CTAP-111-stimulated DNA synthesis 
(P < 0.05). Modest suppression of DNA synthesis re- 
sulted from the inclusion of hydroxychloroquine and in- 
domethasone at clinically relevant concentrations. 
Therapeutic concentrations of phenylbutazone and as- 
pirin produced major reductions in CTAP-enhanced 
DNA synthesis. In several additional experiments (data 
not shown) it appeared that the marked suspension of 
DNA synthesis seen with aspirin was primarily 
achieved at the higher concentrations, since inclusion of 
the agent at levels corresponding to 15 mg % was essen- 
tially without effect. Significant suppression began at 
about 20 mg % (200 pg/ml). The marked suppression of 
CTAP-111 induced DNA synthesis seen with proprano- 
lo1 and imipramine at 10-4M was still present at the 
lO-’M, but either absent or very minor at lO+M. These 
data suggest the possibility of using selected drugs to 
achieve control of precise biochemical actions in cir- 
cumstances where CTAP-I11 plays a pathogenetic role. 
Serotonin, 50 pg/ml, and bradykinin, 25 &ml, had no 
direct effect in accelerating fibroblast DNA synthesis 
and clearly did not potentiate the effect of CTAP-I11 at 
these concentrations. 
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Figure 6. /3-thromboglobulin was recognized by 3 different antisera 
against CTAP-Ill and antisera raised against LA-PF,, but not by 
antisera against PF,. 
Relationship of CTAP-I11 to LA-PF, and P-TG. 
CTAP-I11 and LA-PF, have the same electrophoretic 
mobility in both SDS (22) and acid-urea (23) poly- 
acrylamide disc gel systems, and the amino acid compo- 
sition of LA-PF, (28) is nearly identical to that of 
CTAP-I11 shown in Table 2. Similarly, P-TG resembles 
CTAP-I11 in its amino acid composition (28) and elec- 
trophoretic mobility in disc gel electrophoretic systems 
(data not shown). Immunodiffusion studies suggest 
shared antigenic determinants in CTAP-111, LA-PF,, 
and P-TG since these peptides give precipitin lines of 
identity when reacted with mouse anti-CTAP-I11 or 
rabbit anti-LA-PF, (Figures 5 and 6). Neither CTAP-I 
nor CTAP-I1 reacted with antisera to CTAP-I11 when 
tested by immunodiffusion. It was of interest that radio- 
immunoassay of highly purified P-TG and CTAP-111, 
using commerical reagents for measurement of P-TG, 
gave concentration values close to those based on pro- 
tein determination. Bioassay of LA-PF, showed that it 
possessed the same activities known for CTAP-I11 
(Table 7). LA-PF, proved to be a potent stimulator of 
DNA synthesis in synovial cell cultures, to stimulate 
hyaluronic acid formation in such cultures (measured in 
terms of uronic acid), and to stimulate incorporation of 
‘“C-glucosamine into GAG secreted by these cells. P- 
thromboglobulin caused very modest stimulation of 
GAG synthesis and barely detectable stimulation of 
DNA synthesis in human cells. 
DISCUSSION 
The amino acid composition of apparently ho- 
mogeneous preparations of CTAP-I11 from human 
platelets was determined. Homogeneity was suggested 
by a single protein band on SDS and acid-urea disc gel 
polyacrylamide electrophoresis (4), as well as by the 
demonstration of near integral values for all amino acid 
residues. In addition, radioiodination of CTAP-I11 
failed to identify contaminant proteins detectable by 
SDS or acid-urea gel electrophoresis. 
In general, the similarities in the amino acid 
composition of CTAP-I and -111 were more striking 
than their differences. Even CTAP-I1 differed primarily 
in an excessive representation of only four residues (gly- 
cine, histidine, serine, and alanine). One of the unusual 
features of CTAP-111, as predicted by its thiol lability, 
was the demonstration of two intramolecular disulfide 
links. 
CTAP-I11 is released from human platelets not 
only by addition of bovine thrombin, but also in the 
course of spontaneous blood clotting in vitro. Clearly, 
the extrusion of CTAP-I11 from platelets during clotting 
imparts a major mitogenic principle to the serum. The 
apparent identity of CTAP-I11 (isolated from platelets) 
and LA-PF, (isolated from the extracellular milieu after 
thrombin-induced release) suggests that CTAP-I11 un- 
dergoes no obvious biochemical alteration concomitant 
with discharge from the platelet. 
While CTAP-I11 was shown to stimulate DNA 
and GAG synthesis in several kinds of adult human pri- 
mary connective tissue cell strains, a more extensive sur- 
vey of cell types is justified. The responsiveness of 
osteoblasts, mesothelial cells, and embryonic or fetal 
connective tissue cells is yet unknown. Present data sug- 
Table 7. Biologic activities of  LA-PF, 
Hyaluronate synthesis rate 
(pg HA/mg cell protein 
Sample (CPM/8000 cells) /24 hrs) 
1.0 f 0.5 Buffer 512 f 189 
LA-PF,* 51,929 f 3,312 28.6 f 0.1 
(148 fig protein/rnl) 
[’HI-Thymidine uptake, 
(16.2 pg protein/ml) 
*LA-PF, was the fraction eluted from a heparin-agarose column 
with 0.25 M NaCI. 
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Table 8. Properties of growth factors 
Stimulates Stimulates 
Factor Source weight stability lability composition glycolysis synthesis synthesis 
Molecular Heat Thiol Amino acid* Stimulates DNA GAG 
CTAP-111 (4) Platelets I 1,630 Yes Yes Known Yes Yes Yes 
LA-PF, (28) Platelets 13,700 ? ? Known Yes Yes Yes 
P-Thromboglobulin (29) Platelets 10,700 ? ? Known ? k Yes 
(agrees) 
(agrees) 
Serum growth factor (35) Platelets 13,000 Yes Yes ? ? Yes ? 
Platelet growth factor (30) Platelets 13,000 ? ? ? ? Yes ? 
FGF (37) Bovine 13,000 ? ? Known ? Yes ? 
pituitary (disagrees) 
gland 
* Where the amino acid composition is known, the term “agrees” relates to similarity in composition to CTAP-I11 as recorded in Table I .  
gest that human CTAP-I11 is active in other species, but 
is usually not mitogenic for established cell lines. 
CTAP-I11 was as stimulatory for adult human 
synovial cultures as bovine FGF, more potent than 
TSH, LH, and insulin, and not modified by simultane- 
ous addition of cortisol. Several antirheumatic drugs, 
particularly aspirin, clearly reduced the mitogenic re- 
sponse to CTAP-I11 in vitro. 
Properties of five platelet derived substances and 
bovine pituitary FGF are compared in Table 8. CTAP- 
I11 and LA-PF,, in addition to the tabulated similarities, 
appear identical on electrophoretic and antigenic bases 
as well. P-thromboglobulin is listed in the table because 
of evidence (19,29) indicating that it shares many mo- 
lecular characteristics including antigenic determinants 
and an amino acid compositional pattern with CTAP- 
I11 and LA-PF,. The reason for its attenuated biologic 
properties is yet unclear. Human “serum growth fac- 
tor,” (35) a platelet derived substance, and primate 
platelet mitogen (30) resemble CTAP-I11 and LA-PF, as 
E T I O L O G I C  A G E N T S  ( I N J U R Y )  
t
ALTERED 4 PROTEINS 
LENERGY METABOLISM 
2. CELL PR 0 L1 F E  RAT ION 
3.HYALURONATE SYNTHESIS 
4. COLLAGEN DESPOSlTl ON 
C T A P -  ex 5.ENZYMATl C “REMODELING” 
: 
HEALED SCAR 
Figure 7. This diagrammatic representation of the inflammatory process highlights the sources of con- 
nective tissue activating peptides and their respective actions on connective tissue cells. 
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judged by the published characterization of these mate- 
rials. Clearly, more data are required to establish 
whether the “serum growth factor” is a different entity 
than CTAP-111. Indeed, recently reported studies sug- 
gest that human platelets may contain more than one 
mitogenic principle (36). Our experience supports this 
view. Bovine pituitary FGF is clearly different than 
CTAP-I11 in its aspartic acid, proline, half cystine, me- 
thionine, isoleucine, and leucine content (37). 
The fact that CTAP-I11 acts on human cells at a 
somewhat higher concentration than that reported for 
other platelet preparations raises the possibility that the 
biologic activity resides in a trace impurity rather than 
the major protein that has been isolated. However, the 
co-purification of the GAG and DNA stimulating activ- 
ity, the sensitivity of both activities to thiols, and their 
insensitivity to heat all argue that both activities reside 
in the same molecule. The elution of CTAP-I11 of high 
purity possessing GAG and DNA stimulating activity 
from a specific immunoabsorbent also favors the view 
that CTAP-I11 possesses both biologic activities, and 
that neither is likely to result from trace contamination 
with an unrecognized agent. 
A platelet-derived mediator with the biologic ac- 
tions shown for CTAP-I11 might play an important role 
in inflammatory, atherosclerotic, and thrombotic proc- 
esses. A schematic view of the inflammatory process is 
presented in Figure 7. CTAP-I11 is cast in the role of 
regulating the transition from the acute (vascular) phase 
of inflammation to the reparative (proliferative, con- 
nective tissue) phase of the inflammatory reaction. 
“CTAP-ex” refers to a stimulatory principle in poly- 
morphonuclear leukocytes whose characteristics are un- 
der study. Implicit in this diagram is the idea that 
CTAP-I11 is an autacoid mediator and therefore acts lo- 
cally on cells near the site of platelet aggregation and re- 
lease. The relatively high concentrations of CTAP-I11 
(lo-’ M) required to stimulate adult human connective 
tissue cells are not likely to occur at a great distance 
from actively secreting platelets. The question of 
whether CTAP-I11 is synthesized by the megakaryocyte, 
or platelet, or merely transported by the platelet after 
synthesis elsewhere is yet unclear. 
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